Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 30015-30016 [2012-12276]

Download as PDF 30015 Federal Register / Vol. 77, No. 98 / Monday, May 21, 2012 / Notices There is no cost to respondents other than their time. ESTIMATED ANNUALIZED BURDEN HOURS Respondents Number of respondents Number of responses per respondent Average burden per response (in hours) Total burden (in hours) EMS workers ................................................................................................... 150 1 20/60 50 ........................ ........................ ........................ 50 Total .......................................................................................................... both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kimberly S. Lane, Deputy Director, Office of Science Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. Dated: May 15, 2012. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2012–12287 Filed 5–18–12; 8:45 am] BILLING CODE 4163–18–P [FR Doc. 2012–12281 Filed 5–18–12; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review Centers for Disease Control and Prevention The meeting announced below concerns Characterizing the Short and Long Term Consequences of Traumatic Brain Injury (TBI) among Children in the United States (FOA) CE12–004, initial review. In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting: ebenthall on DSK5SPTVN1PROD with NOTICES Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) Time and Date: 1:00 p.m.–5:00 p.m., June 11, 2012 (Closed). Place: Crowne Plaza Hotel Atlanta Perimeter at Ravinia, 4355 Ashford Dunwoody Road, Atlanta, Georgia 30346. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters To Be Discussed: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘Characterizing the Short and Long Term Consequences of Traumatic Brain Injury (TBI) among Children in the United States, FOA CE12–004.’’ Contact Person for More Information: J. Felix Rogers, Ph.D., M.P.H., Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F63, Atlanta, Georgia 30341, Telephone (770) 488–4334. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for VerDate Mar<15>2010 18:18 May 18, 2012 Jkt 226001 In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announce the following meeting of the aforementioned committee: Times and Dates: 8:00 a.m.–5:00 p.m., June 20, 2012, 8:00 a.m.–1:00 p.m., June 21, 2012. Place: CDC, Tom Harkin Global Communications Center, 1600 Clifton Road NE., Building 19, Kent ‘‘Oz’’ Nelson Auditorium, Atlanta, Georgia 30333. Status: Open to the public, limited only by the space available. Purpose: The committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines. Further, under provisions of the Affordable Care Act, at section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been adopted by the Director of the Centers for Disease Control and Prevention must be covered by applicable health plans. Matters To Be Discussed: The agenda will include discussions on: adult immunization, human papillomavirus vaccines, hepatitis B vaccine, meningococcal vaccines, influenza, PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 pneumococcal vaccines, measles-mumpsrubella vaccine, pertussis, development of evidence-based recommendations, Institute of Medicine vaccine committee report, and anthrax vaccine adsorbed and vaccine supply. Recommendation votes are scheduled for pneumococcal vaccines and for influenza. Time will be available for public comment. Agenda items are subject to change as priorities dictate. Meeting is webcast live via the World Wide Web; for instructions and more information on ACIP please visit the ACIP Web site: https://www.cdc.gov/vaccines/recs/acip/. Contact Person for More Information: Stephanie B. Thomas, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road NE., MS–A27, Atlanta, Georgia 30333, Telephone (404) 639–8836; Email ACIP@CDC.GOV. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Dated: May 15, 2012. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2012–12279 Filed 5–18–12; 8:45 am] BILLING CODE 4160–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review The meeting announced below concerns Field Triage of Traumatic Brain Injury (TBI) in Older Adults Taking Anticoagulants or Platelet Inhibitors, Funding Opportunity Announcement (FOA) CE12–005, initial review. E:\FR\FM\21MYN1.SGM 21MYN1 30016 Federal Register / Vol. 77, No. 98 / Monday, May 21, 2012 / Notices In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting: Time and Date: 8:00 a.m.–12:00 p.m., June 11, 2012 (Closed). Place: Crowne Plaza Hotel Atlanta Perimeter at Ravinia, 4355 Ashford Dunwoody Road, Atlanta, Georgia 30346. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters To Be Discussed: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘Field Triage of Traumatic Brain Injury (TBI) in Older Adults Taking Anticoagulants or Platelet Inhibitors, FOA CE12–005.’’ Contact Person for More Information: J. Felix Rogers, Ph.D., M.P.H., Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F63, Atlanta, Georgia 30341, Telephone (770) 488–4334. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Dated: May 15, 2012. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2012–12276 Filed 5–18–12; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2012–N–0377] Clinical Study Design and Performance of Hospital Glucose Sensors AGENCY: Food and Drug Administration, HHS. Notice of public meeting; request for comments. ebenthall on DSK5SPTVN1PROD with NOTICES ACTION: The Food and Drug Administration (FDA) is announcing the following public meeting entitled ‘‘Clinical Study Design and Performance of Hospital Glucose Sensors.’’ The purpose of this public meeting is to discuss clinical study design considerations and performance metrics for innovative glucose sensors intended to be used in hospital point of care settings. DATES: Date and Time: The public meeting will be held on June 25, 2012, from 8 a.m. to 5 p.m. VerDate Mar<15>2010 18:18 May 18, 2012 Jkt 226001 Location: The meeting will be held at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31, the Great Room (rm. 1503), Silver Spring, MD 20993. Entrance for the public meeting participants (non-FDA employees) is through Building 1 where routine security check procedures will be performed. For parking and security information, please refer to https://www. fda.gov/AboutFDA/WorkingatFDA/ BuildingsandFacilities/WhiteOak CampusInformation/ucm241740.htm. The public meeting will also be available to be viewed online via webcast. Contact: Vicki Moyer, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5626, Silver Spring, MD 20993, 301–796– 6148, FAX: 301–847–8513, email: vicki.moyer@fda.hhs.gov. Registration: Registration is free and on a first-come, first-served basis. Persons interested in attending this meeting must register online by 4 p.m., June 15, 2012. Early registration is recommended because facilities are limited and, therefore, FDA may limit the number of participants from each organization. If time and space permits, onsite registration on the day of the meeting will be provided beginning at 7 a.m. If you need special accommodations due to a disability, please contact Susan Monahan, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 4321, Silver Spring, MD 20993, 301–796–5661, email: susan.monahan@fda.hhs.gov, no later than June 15, 2012. To register for the public meeting, please visit FDA’s Medical Devices News & Events—Workshops & Conferences calendar at https://www.fda. gov/MedicalDevices/NewsEvents/Work shopsConferences/default.htm. (Select this public meeting from the posted events list.) Please provide complete contact information for each attendee, including name, title, affiliation, address, email, and telephone number. Those without Internet access should contact Susan Monahan to register (see Registration section of this document). Registrants will receive confirmation after they have been accepted. You will be notified if you are on a waiting list. Streaming Web cast of the Public Meeting: This public meeting will also be Web cast. Persons interested in viewing the Web cast must register online by 4 p.m., June 15, 2012. Early registration is recommended because Web cast connections are limited. Organizations are requested to register PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 all participants, but to view using one connection per location. Web cast participants will be sent technical system requirements after registration and will be sent connection access information after June 20, 2012. If you have never attended a Connect Pro event before, test your connection at https://collaboration.fda.gov/common/ help/en/support/meeting_test.htm. To get a quick overview of the Connect Pro program, visit https://www.adobe.com/ go/connectpro_overview. (FDA has verified the Web site addresses in this document, but FDA is not responsible for any subsequent changes to the Web sites after this document publishes in the Federal Register.) Requests for Oral Presentations: This public meeting includes a public comment session. During online registration you may indicate if you wish to speak and the proposed title for the public comment session, and which topics you wish to address. FDA has included general topics in this document. FDA will do its best to accommodate requests to make public comment. Following the close of registration, FDA will determine the amount of time allotted to each speaker and will select and notify participants by June 19, 2012. No commercial or promotional material will be permitted to be presented or distributed at the meeting. Comments: FDA is holding this public meeting to obtain information on innovative kinds of hospital glucose sensors. In order to permit the widest possible opportunity to obtain public comment, FDA is soliciting electronic or written comments on all aspects of the meeting topics. The deadline for submitting comments related to this public meeting is July 23, 2012. Regardless of attendance at the public meeting, interested persons may submit either electronic or written comments. Submit electronic comments to https:// www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. It is only necessary to send one set of comments. Please identify comments with the docket number found in brackets in the heading of this document. In addition, when responding to specific questions as outlined in section II of this document, please identify the question you are addressing. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday and will be posted to the docket at https:// www.regulations.gov. E:\FR\FM\21MYN1.SGM 21MYN1

Agencies

[Federal Register Volume 77, Number 98 (Monday, May 21, 2012)]
[Notices]
[Pages 30015-30016]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-12276]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP): Initial Review

    The meeting announced below concerns Field Triage of Traumatic 
Brain Injury (TBI) in Older Adults Taking Anticoagulants or Platelet 
Inhibitors, Funding Opportunity Announcement (FOA) CE12-005, initial 
review.

[[Page 30016]]

    In accordance with Section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the aforementioned meeting:

    Time and Date: 8:00 a.m.-12:00 p.m., June 11, 2012 (Closed).
    Place: Crowne Plaza Hotel Atlanta Perimeter at Ravinia, 4355 
Ashford Dunwoody Road, Atlanta, Georgia 30346.
    Status: The meeting will be closed to the public in accordance 
with provisions set forth in Section 552b(c) (4) and (6), Title 5 
U.S.C., and the Determination of the Director, Management Analysis 
and Services Office, CDC, pursuant to Public Law 92-463.
    Matters To Be Discussed: The meeting will include the initial 
review, discussion, and evaluation of applications received in 
response to ``Field Triage of Traumatic Brain Injury (TBI) in Older 
Adults Taking Anticoagulants or Platelet Inhibitors, FOA CE12-005.''
    Contact Person for More Information: J. Felix Rogers, Ph.D., 
M.P.H., Scientific Review Officer, CDC, 4770 Buford Highway NE., 
Mailstop F63, Atlanta, Georgia 30341, Telephone (770) 488-4334.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining 
to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention 
and the Agency for Toxic Substances and Disease Registry.

    Dated: May 15, 2012.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2012-12276 Filed 5-18-12; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.